Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells $28,224.00 in Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 8,064 shares of the stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $3.50, for a total value of $28,224.00. Following the completion of the transaction, the insider now directly owns 1,255,730 shares in the company, valued at approximately $4,395,055. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Monday, April 22nd, Aladar Szalay sold 14,331 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total value of $50,588.43.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total transaction of $171,850.99.

Genelux Price Performance

NASDAQ GNLX opened at $3.40 on Friday. The stock’s fifty day moving average price is $5.67 and its 200 day moving average price is $10.76. Genelux Co. has a 1 year low of $3.07 and a 1 year high of $40.98.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings results on Friday, March 29th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.04). Sell-side analysts forecast that Genelux Co. will post -0.81 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Woodward Diversified Capital LLC grew its position in Genelux by 2,326.2% during the 4th quarter. Woodward Diversified Capital LLC now owns 1,082,270 shares of the company’s stock worth $15,163,000 after purchasing an additional 1,037,663 shares during the period. Vanguard Group Inc. raised its position in Genelux by 1,660.1% during the third quarter. Vanguard Group Inc. now owns 980,993 shares of the company’s stock valued at $24,025,000 after acquiring an additional 925,258 shares in the last quarter. Provident Wealth Management LLC acquired a new position in Genelux in the third quarter valued at approximately $8,211,000. Bank of New York Mellon Corp grew its stake in shares of Genelux by 476.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 53,938 shares of the company’s stock worth $1,321,000 after purchasing an additional 44,584 shares during the period. Finally, AMG National Trust Bank purchased a new position in shares of Genelux during the 3rd quarter valued at approximately $1,233,000. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on GNLX shares. HC Wainwright cut their price objective on shares of Genelux from $35.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. Benchmark restated a “speculative buy” rating and set a $30.00 price objective on shares of Genelux in a research note on Wednesday, April 3rd.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.